Tysabri for Crohn’s gets FDA advisory review
FDA's Gastrointestinal Drugs and Drug Safety and Risk Management Advisory Committees will jointly review Biogen Idec/Elan's Tysabri (natalizumab) for moderately to severely active Crohn's disease July 31. Indicated for multiple sclerosis, Tysabri's sNDA includes results of three trials assessing the biologic as both an induction and maintenance therapy. Biogen pulled Tysabri from the market in 2005 after reports of progressive multifocal leukoencephalopathy, and the company is now in the second phase of the drug's relaunch. One of the three reported cases of PML in the Tysabri database was in a Crohn's patient...
You may also be interested in...
Top US FDA device center officials Jeff Shuren and William Maisel said in a 15 April blog post that manufacturers should expect a delay in the review of new product submissions thanks to the pandemic. They noted that the agency also won’t be accepting certain IVD pre-submission requests until next year.
Prescience Point Capital is trying to reshuffle the board of directors leading regenerative medicine company MiMedx, arguing the company’s current board has destroyed shareholder value. The company's tock is selling for about a third of its potential value, according to Prescience.
Unilever’s Suave brand led new sanitizer product sales in 2020, when hand sanitizers total sales grew 569%, according to IRI. Sales of rinseable hand-soap sales grew 64% and antiseptics 19%.